CRSP
Crispr Therapeutics
$46.73
+$0.19 (+0.41%)Jul 27, 2026
Key metrics
The numbers that frame CRSP today
- Market cap
- $4.51B
- P/E (TTM)
- -7.9
- EV / FCF
- -12.1
- Gross margin
- 100%
- EV / Sales
- 1,185.4
- ROIC
- -25.4%
- Div yield
- 0%
- Debt / equity
- 0.4
- 52wk Low
- $44.12
- 52wk High
- $78.48
Growth
Revenue and earnings trend for CRSP
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about CRSP
Is Crispr Therapeutics a good buy?
No. Crispr Therapeutics has poor quality and weak momentum. Both signals point to a weaker setup. Growth looks excellent, which supports the long-term business case, but that is not enough to offset the weak setup. We think Crispr Therapeutics is selling at a very high price.
What is the market capitalization of CRSP?
Crispr Therapeutics's market capitalization is $4.51B.
What is the P/E ratio for CRSP stock?
Crispr Therapeutics's current P/E ratio is -7.9.
What is the 52-week high for CRSP stock?
The 52-week high for Crispr Therapeutics is $78.48. The current close of $46.73 is 40.5% below that high.
What is the 52-week low for CRSP stock?
The 52-week low for Crispr Therapeutics is $44.12. The current close of $46.73 is 5.9% above that low.
Does CRSP stock pay dividends?
Crispr Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for CRSP?
Crispr Therapeutics's Debt / Equity ratio is 0.43.